Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach